Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Practical Application of PARP Inhibitors in Metastatic CRPC

May 24th 2023

Expert panelists consider the real-world application of PARP inhibitor data in patients with metastatic castration-resistant prostate cancer.

Dr Stone on the Association of Language Barriers and PSA Screening for Prostate Cancer

May 19th 2023

Benjamin V. Stone, MD, discusses the association between language barriers and prostate-specific antigen screening rates in American men.

Link Between PSA Response and Survival Outcomes Supports Use of Darolutamide Plus ADT/Docetaxel as a SOC in mHSPC

May 18th 2023

Fred Saad, MD, FRCS, expands on the relationship between PSA responses and survival outcomes in the ARASENS trial, explained the use of 0.2 ng/mL as a standard cut off for undetectable PSA within this exploratory analysis, and discussed how this study elucidates future directions for research with triplet regimens in mHSPC.

Dr Cole on the Rationale for Investigating Race-based Disparities in Prostate Cancer–Specific Survival

May 18th 2023

Alexander Putnam Cole, MD, discusses the rationale for investigating the magnitude of racial and ethnic disparities in prostate cancer–specific survival in patients undergoing surgery vs radiotherapy.

Real-world Evidence Provides More Accurate Representation of Next-generation AR Inhibitor Use and Efficacy in mCSPC

May 17th 2023

Benjamin H. Lowentritt, MD, FACS, highlights key findings from the retrospective study of second-generation ARSI use in patients with metastatic castration-sensitive prostate cancer treated in clinic and discusses several directions for future analyses of real-world outcomes in prostate cancer.

Metastatic CRPC: Advent of PARP Inhibitors

May 17th 2023

Comprehensive insight on the evolving role of PARP inhibitors in metastatic castration-resistant prostate cancer and clinical trials in this setting.

Overview of the Metastatic Castration-Resistant Prostate Cancer Treatment Paradigm

May 17th 2023

Expert oncologists briefly review the current treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC).

Study Sheds Light on Effect of Type of Treatment on Race-based Differences in Prostate Cancer–Specific Survival

May 15th 2023

Alexander Putnam Cole, MD, discusses the importance of investigating racial and ethnic disparities in prostate cancer outcomes, key data from a comparison of cancer-specific survival according to race and treatment modality, and how these results could better inform efforts to improve access to, and quality of, patient care in this disease.

Haffner Highlights Treatment and Research Considerations for Basal Cell Carcinoma of the Prostate

May 11th 2023

Dr Haffner explains distinguishing features between basal cell and adenocarcinoma of the prostate, findings from a genomics study of basal cell prostate carcinoma, and the challenges that arise when diagnosing and treating patients with this rare disease.

Updated Findings Spur Excitement In nmCRPC, mHSPC, mCRPC

May 11th 2023

An increased focus on long-term and genomic analyses on established treatments in prostate cancer have revealed new opportunities for patients across disease states.

Dr Shore on the Rationale for the EMBARK Trial in Nonmetastatic Prostate Cancer

May 10th 2023

Neal Shore, MD, FACS, discusses the rationale for the phase 3 EMBARK trial investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Nivolumab Plus Brachytherapy/ADT Improves Disease Control in Grade Group 5 Prostate Cancer

May 10th 2023

John Michael "JM" Bryant, MD, expands on the results of the interim analysis of the single-center, single-arm phase 2 trial for patients with grade group 5 prostate cancer treated with the combination of nivolumab and standard of care.

Novel Treatment Modalities in Metastatic Hormone-Sensitive Prostate Cancer

May 10th 2023

Closing out their segment on metastatic hormone-sensitive prostate cancer, panelists review other treatment modalities being investigated in clinical trials.

Educating Patients on Treatment Options in Metastatic HSPC

May 10th 2023

Expert insight on methods to educate patients on available treatment options in the setting of metastatic hormone-sensitive prostate cancer.

Short-term QOL Scores Lower in Non-Hispanic Black Patients With Prostate Cancer After Radical Prostatectomy

May 9th 2023

Mara Koelker, MD, discusses the rationale of evaluating racial differences in QOL for patients with prostate cancer and ways to address these short-term disparities in a real-world setting.

Symptomatic Status and Lesion Size of Bone Metastases: Impact on Radiotherapy Selection in mCRPC

May 8th 2023

Drs Manning and Armstrong discuss the impact of lesion size and symptomatic status of bone metastases on radiotherapy selection in mCRPC, highlighting ongoing trials and emerging data.

Closing Thoughts on the Future of mCRPC Treatment

May 8th 2023

Matthew Manning, MD, and Andrew Armstrong, MD, discuss the remaining unmet needs in mCRPC, clinical trials and novel agents to look out for, and share practical advice for other clinicians treating patients with the disease.

Dr Cole on Race-Based Differences in Prostate Cancer–Specific Mortality

May 5th 2023

Alexander Putnam Cole, MD, discusses findings from a study investigating the effect of type of definitive treatment on race-based differences in prostate cancer–specific mortality in patients with prostate cancer.

Limited Drug Antagonism Between Darolutamide and Docetaxel Confirms Efficacy and Tolerability of ARASENS Triplet in mHSPC

May 5th 2023

Bertrand F. Tombal, MD, PhD, explains how data on the clinically relevant drug-drug interactions and TRAEs with darolutamide, docetaxel and ADT support previously reported efficacy data from the ARASENS trial, and presents lingering questions and caveats from this trial that should be addressed through continued research.

Dr Sieber on Comorbidities and the Risk of Cardiovascular Events in Prostate Cancer

May 4th 2023

Paul Sieber, MD, discusses the importance of assessing risk factors for cardiovascular events in patients with prostate cancer who are initiating androgen deprivation therapy.